1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,750 | 7,000 | 13:05 | |
| 6,750 | 7,000 | 12.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | HENLIUS (02696): NEXT DAY DISCLOSURE RETURNS | 3 | HKEx | ||
| Di | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR NEW INDICATION OF HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION ... | 1 | HKEx | ||
| Mo | Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with HLX22 | 267 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 8, 2026 / Alligator Bioscience (STO:ATORX) today comments on a recent update regarding patient recruitment in the ongoing Phase 3 clinical trial of HLX22, developed... ► Artikel lesen | |
| 05.06. | HENLIUS: HLX17 Completes First Patient Dosing in US for International Multi-center Phase 1 Clinical Trial | 1 | AASTOCKS | ||
| 05.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF ... | 1 | HKEx | ||
| 29.05. | HENLIUS: NMPA Approves Hanbeiyou for Neoadjuvant/Adjuvant and Metastatic Treatment of HER2-Positive Early Breast Cancer | 3 | AASTOCKS | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 29.05. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED HANBEIYOU (PERTUZUMAB INJECTION) FOR THE NEOADJUVANT/ADJUVANT ... | 1 | HKEx | ||
| 28.05. | HENLIUS HLX43 for Injection as Monotherapy or in Combination with HLX07 Completes First Patient Dosing in China for Clinical Study | 2 | AASTOCKS | ||
| 28.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2/3 CLINICAL STUDY OF HLX43 FOR INJECTION ... | 1 | HKEx | ||
| 26.05. | HENLIUS: HLX07 International Multi-center Phase 2/3 Clinical Study Completes First Patient Dosing in China | 1 | AASTOCKS | ||
| 26.05. | HENLIUS HLX15-SC Completes First Patient Dosing in China for International Multi-center Phase 1 Trial in NDMM | 2 | AASTOCKS | ||
| 26.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 2/3 CLINICAL STUDY COMPARING PIMURTAMAB ... | - | HKEx | ||
| 26.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF HLX15-SC (RECOMBINANT ... | - | HKEx | ||
| 22.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - SERPLULIMAB INJECTION (TRADE NAME IN CHINESE MAINLAND: HANSIZHUANG; TRADE NAME IN THE EUROPEAN UNION: HETRONIFLY) ... | - | HKEx | ||
| 22.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX316 FOR INJECTION (B7-H3-TARGETING SIALIDASE ... | 1 | HKEx | ||
| 22.05. | Alligator Bioscience Comments on Henlius Update on Long-Term Follow-Up Data for HLX22 | 321 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 22, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today comments on a recent update shared by Shanghai Henlius Biotech, Inc. regarding long-term follow-up observations... ► Artikel lesen | |
| 21.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN AN EU COUNTRY (SPAIN) HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTRE PHASE 2 CLINICAL STUDY ... | 2 | HKEx | ||
| 21.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1XCD3XCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF ... | - | HKEx | ||
| 21.05. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG ... | - | HKEx | ||
| 19.05. | HENLIUS (02696): POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 19 MAY 2026 | 1 | HKEx |
1 2 3 4 5 Weiter >>
89 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 88,33 | 0,00 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 46,130 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| QIAGEN | 31,980 | -0,28 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,000 | -0,07 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| IMMUNOME | 18,380 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 30,960 | +0,06 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| MBX BIOSCIENCES | 35,510 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| IMMUNOVANT | 33,620 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,07 | +0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 8,210 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 34,830 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| ALUMIS | 24,170 | +0,08 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,080 | -0,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,950 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,590 | -0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) |
Das Unternehmen SHANGHAI HENLIUS BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +7,81 % bei einem Aktienkurs von 6,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.